IRWD
BEARISH
$3.63
Live
Ironwood Pharmaceuticals, Inc. · NASDAQ
Target $6.1
(+68.0%)
$0.53
52W Range
$5.78
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$591.9M
P/E
24.2
ROE
N/A
Profit margin
8.1%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Ironwood Pharmaceuticals presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a critical lack of equity, as evidenced by a negative Price/Book ratio of -2.26. While the stock has seen a massive 1-year price surge, this is fundamentally unsupported by a 47.3% collapse in year-over-year revenue and a significant disconnect between the current price ($3.63) and the growth-based intrinsic value ($1.05). Heavy insider selling totaling nearly $22 million further signals a lack of confidence from company leadership.
Key Strengths
Strong gross margins (67.88%)
Positive operating margin (13.73%)
Recent 1-year price momentum (+259.4%)
Positive ROA (19.85%)
Current ratio above 1.0 (1.13), indicating short-term liquidity
Key Risks
Negative shareholders' equity (Price/Book: -2.26)
Severe revenue contraction (-47.3% YoY)
Significant overvaluation relative to intrinsic value ($3.63 vs $1.05)
Aggressive insider selling ($21.96M in last 6 months)
Bearish technical trend (0/100)
AI Fair Value Estimate
Based on comprehensive analysis
$1.05
-71.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
20
15
40
45
0
AI Verdict
Speculative/High Risk
Key drivers: Negative Equity, Revenue Collapse, Insider Dumping, Intrinsic Value Gap
Confidence
90%
Value
20/100
Ref P/E, Price/Book, and Intrinsic Value
Positives
- Low Forward P/E (2.49) if earnings projections materialize
Watchpoints
- Price/Book is negative
- Trading at 3.4x intrinsic value
- P/E of 24.20 is high for crashing revenue
Future
15/100
Ref Growth rates
Positives
- Analyst target price of $6.10 suggests potential upside
Watchpoints
- Revenue growth is -47.3%
- EPS growth is -150% YoY
- Q/Q revenue growth is -47.31%
Past
40/100
Ref Historical trends
Positives
- Strong 1-year recovery (+259%)
Watchpoints
- 5-year change is -64.3%
- 3-year change is -66.3%
- Erratic earnings surprise history
Health
45/100
Ref Piotroski F-Score and Price/Book
Positives
- Piotroski F-Score of 4/9 is stable
- Current ratio 1.13
Watchpoints
- Negative equity (Price/Book -2.26)
- Lack of Altman Z-Score data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.63
Analyst Target
$6.1
Upside/Downside
+68.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IRWD and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IRWD
Ironwood Pharmaceuticals, Inc.
Primary
|
-64.3% | -66.3% | +259.4% | +128.3% | -1.4% | +2.5% |
|
HSTM
HealthStream, Inc.
Peer
|
-8.4% | -25.8% | -36.2% | -22.1% | -3.1% | -2.8% |
|
BVS
Bioventus Inc.
Peer
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
|
ESPR
Esperion Therapeutics, Inc.
Peer
|
-91.3% | +70.1% | +119.8% | -9.3% | -23.4% | -10.7% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
IRW
Ironwood Pharmaceuticals, Inc.
Primary
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%
HST
HealthStream, Inc.
Peer
5Y
-8.4%
3Y
-25.8%
1Y
-36.2%
6M
-22.1%
1M
-3.1%
1W
-2.8%
BVS
Bioventus Inc.
Peer
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
ESP
Esperion Therapeutics, Inc.
Peer
5Y
-91.3%
3Y
+70.1%
1Y
+119.8%
6M
-9.3%
1M
-23.4%
1W
-10.7%
AVN
Avanos Medical, Inc.
Peer
5Y
-72.6%
3Y
-56.0%
1Y
-17.1%
6M
+9.0%
1M
+14.8%
1W
+6.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
24.2
Forward P/E
2.49
PEG Ratio
N/A
P/B Ratio
-2.26
P/S Ratio
2.0
EV/Revenue
3.29
EV/EBITDA
8.08
Market Cap
$591.9M
Profitability
Profit margins and return metrics
Profit Margin
8.11%
Operating Margin
13.73%
Gross Margin
67.88%
ROE
N/A
ROA
19.85%
Growth
Revenue and earnings growth rates
Revenue Growth
-47.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-47.31%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.13
Good
Quick Ratio
1.08
Good
Cash/Share
$1.32
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
13.7%
Net Margin
-4.8%
Total Assets
$0.4B
Liabilities
$0.7B
Equity
$-0.3B
Debt/Equity
-2.52x
Operating CF
$0.1B
Free Cash Flow
$0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-25
$-0.01
-200.0% surprise
2025-11-10
$0.23
+97.1% surprise
2025-08-07
$0.14
+500.1% surprise
Healthcare Sector Comparison
Comparing IRWD against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
P/E Ratio
24.2
This Stock
vs
88.64
Sector Avg
-72.7%
(Discount)
Profit Margin
8.11%
This Stock
vs
-19.58%
Sector Avg
-141.4%
(Weaker)
Revenue Growth
-47.3%
This Stock
vs
88.16%
Sector Avg
-153.7%
(Slower)
Current Ratio
1.13
This Stock
vs
3.58
Sector Avg
-68.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
BEARISH | $591.9M | 24.2 | -% | 8.1% | $3.63 | |
|
HSTM
HealthStream, Inc.
|
BEARISH | $589.8M | 32.59 | 5.1% | 6.0% | $19.88 | Compare |
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | Compare |
|
ESPR
Esperion Therapeutics, Inc.
|
NEUTRAL | $598.37M | - | -% | -5.6% | $2.33 | Compare |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
IRWD
Ironwood...
BEARISH
Mkt Cap
$592M
P/E
24.2
ROE
-%
Price
$3.63
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-17 | DENNER ALEXANDER J | Director | Sale | 6,730,800 | $20,530,448 |
| 2026-03-13 | DENNER ALEXANDER J | Director | Stock Award | 4,451 | - |
| 2026-03-10 | MCCOURT THOMAS A | Chief Executive Officer | Stock Award | 409,836 | - |
| 2026-03-10 | SHETZLINE MICHAEL | Officer | Stock Award | 136,612 | - |
| 2026-03-10 | SILVER RONALD | Officer | Stock Award | 163,934 | - |
| 2026-03-10 | MINARDO JOHN | Officer | Stock Award | 136,612 | - |
| 2026-03-10 | MARTINI GREGORY S. | Chief Financial Officer | Stock Award | 136,612 | - |
| 2026-03-10 | GASKINS TAMMI L | Officer | Stock Award | 136,612 | - |
| 2026-02-24 | MCCOURT THOMAS A | Chief Executive Officer | Sale | 198,283 | $739,929 |
| 2026-02-24 | SHETZLINE MICHAEL | Officer | Sale | 32,582 | $121,586 |
| 2026-02-24 | SILVER RONALD | Officer | Sale | 24,173 | $90,206 |
| 2026-02-24 | MINARDO JOHN | Officer | Sale | 36,492 | $136,177 |
| 2026-02-24 | MARTINI GREGORY S. | Chief Financial Officer | Sale | 21,944 | $81,888 |
| 2026-02-24 | GASKINS TAMMI L | Officer | Sale | 21,526 | $80,328 |
| 2026-01-05 | SILVER RONALD | Officer | Sale | 35,416 | $162,914 |
DENNER ALEXANDER J
Director
2026-03-17
6,730,800 shares
·
$20,530,448
DENNER ALEXANDER J
Director
2026-03-13
4,451 shares
MCCOURT THOMAS A
Chief Executive Officer
2026-03-10
409,836 shares
SHETZLINE MICHAEL
Officer
2026-03-10
136,612 shares
SILVER RONALD
Officer
2026-03-10
163,934 shares
MINARDO JOHN
Officer
2026-03-10
136,612 shares
MARTINI GREGORY S.
Chief Financial Officer
2026-03-10
136,612 shares
GASKINS TAMMI L
Officer
2026-03-10
136,612 shares
MCCOURT THOMAS A
Chief Executive Officer
2026-02-24
198,283 shares
·
$739,929
SHETZLINE MICHAEL
Officer
2026-02-24
32,582 shares
·
$121,586
SILVER RONALD
Officer
2026-02-24
24,173 shares
·
$90,206
MINARDO JOHN
Officer
2026-02-24
36,492 shares
·
$136,177
MARTINI GREGORY S.
Chief Financial Officer
2026-02-24
21,944 shares
·
$81,888
GASKINS TAMMI L
Officer
2026-02-24
21,526 shares
·
$80,328
SILVER RONALD
Officer
2026-01-05
35,416 shares
·
$162,914
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
Citizens
2026-02-26
Market Outperform
Market Outperform
Wells Fargo
2026-01-05
Equal-Weight
Equal-Weight
Citizens
2026-01-05
Market Perform
Market Outperform
Wells Fargo
2025-11-11
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning IRWD from our newsroom.
Newest → oldest
No matching news yet.